4 completed, 1 recruiting, 1 terminated. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow GVHD, Acute: new trials by email Literature Review of GVHD, Acute trials Research Report on GVHD, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) Ruxolitinib and Methylprednisolone, Methylprednisolone - GVHD, Acute, Stem Cell Transplant Complications | Phase 2 | Recruiting | Daihong Liu | 54 | 2025-06-30 | 2026-04-03 |
| Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT Decidua Stroma Cells (DSC), Best available Treatment (BAT) - GVHD, Acute | Phase 2 | Terminated | Mats Remberger | 12 | 2021-12-01 | 2026-05-06 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease BMS-986004, Sirolimus, Tacrolimus - Graft-versus-host-disease, GVHD | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 45 | 2019-02-15 | 2026-04-02 |
| PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT PT-CY-FK +/-ATG - GVHD, Acute | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 23 | 2019-01-01 | 2021-05-21 |
| To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids Methotrexate, Placebo - Allogeneic Disease, GVH - Graft Versus Host Reaction | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 104 | 2018-08-16 | 2026-09-18 |
Graft vs Host Disease (6) · Bronchiolitis Obliterans Syndrome (1)
Immune System Diseases (6) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Organizing Pneumonia (1) · Respiratory Tract Diseases (1)
Sirolimus (2) · ruxolitinib (2) · Eosinophil Cationic Protein (1) · Etanercept (1) · Everolimus (1) · Infliximab (1) · Methotrexate (1) · Methylprednisolone (1) · Standard of Care (1) · Tacrolimus (1) · itolizumab (1) · vedolizumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Biocon Limited (1) · Daihong Liu (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Mats Remberger (1) · Shanghai Jiao Tong University School of Medicine (1)
China (2) · United States (2) · Denmark (1) · France (1) · Norway (1) · Sweden (1)
Farhad Khimani, M.D. (1) · Jiong Hu (1) · Joel Rothman (1) · Mats Remberger, Professor (1) · Mohamad Mohty, PU-PH (1)
PMID 29533533, PMID 31173898, PMID 33816524, PMID 35484649
2017 (1), 2019 (1)